Diagnosis & Disease Information

Study Shows Advantages of Degarelix

MILAN—The investigational agent degarelix provides more rapid and profound testosterone suppression than conventional androgen deprivation therapy in men with advanced prostate cancer, researchers reported. Degarelix is a new synthetic peptide gonadotropin-releasing hormone (GnRH) blocker.

Novel Therapy Eases IC/PBS Symptoms

MILAN—Intravesical alkalized lidocaine (PSD597) may be an effective short-term and possibly long-term treatment for patients with interstitial cystitis/painful bladder syndrome (IC/PBS), data suggest.

Early Graft Declotting May Be Bad

WASHINGTON, D.C.—Percutaneous declotting of hemodialysis grafts less than 30 days from initial placement may result in shorter secondary patency compared with declotting of older grafts, according to researchers.

Managing UTIs in Debilitated Patients

Infections are a serious complication and leading cause of death in debilitated patients, including those with cancer, immunosuppression (e.g., transplantation or AIDS patients), diabetes, chronic renal failure, severe neurologic conditions such as Parkinsonism or spinal cord injury, and the elderly.

Next post in Malpractice News